Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
5.89
-0.04 (-0.59%)
At close: Dec 5, 2025, 4:00 PM EST
5.77
-0.12 (-1.95%)
After-hours: Dec 5, 2025, 4:10 PM EST
Company Description
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases.
Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024.
The company was incorporated in 2019 and is based in Palo Alto, California.
Kalaris Therapeutics, Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Andrew Oxtoby |
Contact Details
Address: 628 Middlefield Road Palo Alto, California 94301 United States | |
| Website | kalaristx.com |
Stock Details
| Ticker Symbol | KLRS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001754068 |
| CUSIP Number | 482929106 |
| ISIN Number | US4829291065 |
| Employer ID | 83-1971007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Andrew Oxtoby | President, Chief Executive Officer and Director |
| Dr. Srinivas Akkaraju M.D., Ph.D. | Director and Co-Founder |
| Dr. Michael Philip Dybbs Ph.D. | Director and Co-Founder |
| Dr. Napoleone Ferrara M.D. | Independent Director and Co-Founder |
| Matthew Gall M.B.A. | Chief Financial Officer and Treasurer |
| Brett R. Hagen | Chief Accounting Officer |
| Dr. Matthew Feinsod M.D. | Chief Medical Officer |
| Kristine Curtiss | Senior Vice President of Clinical |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 12, 2025 | 8-K | Current Report |
| Nov 3, 2025 | 8-K | Current Report |
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Aug 13, 2025 | 8-K | Current Report |
| Aug 13, 2025 | 8-K | Current Report |
| Jul 29, 2025 | SCHEDULE 13G/A | Filing |
| Jul 1, 2025 | ARS | Filing |
| Jul 1, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 1, 2025 | DEF 14A | Other definitive proxy statements |